Compare BWEN & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BWEN | CTSO |
|---|---|---|
| Founded | N/A | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.0M | 45.7M |
| IPO Year | 2009 | 2008 |
| Metric | BWEN | CTSO |
|---|---|---|
| Price | $2.53 | $0.74 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $6.00 | $5.38 |
| AVG Volume (30 Days) | ★ 243.5K | 64.9K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $146,785,000.00 | $22,503,908.00 |
| Revenue This Year | $11.75 | $7.29 |
| Revenue Next Year | N/A | $8.91 |
| P/E Ratio | $9.17 | ★ N/A |
| Revenue Growth | N/A | ★ 48.53 |
| 52 Week Low | $1.41 | $0.60 |
| 52 Week High | $4.15 | $1.39 |
| Indicator | BWEN | CTSO |
|---|---|---|
| Relative Strength Index (RSI) | 44.13 | 65.19 |
| Support Level | $1.87 | $0.61 |
| Resistance Level | $2.78 | $1.02 |
| Average True Range (ATR) | 0.14 | 0.04 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 57.32 | 91.86 |
Broadwind Inc is a precision manufacturer of structures, equipment and components for clean technology and other specialized applications. The company provide technologically high value products to customers with complex systems and stringent quality standards that operate in energy, mining and infrastructure sectors, in the United States of America. It capabilities include heavy fabrications, welding, metal rolling, coatings, gear cutting and shaping, gearbox manufacturing and repair, heat treat, assembly, engineering and packaging solutions. It operates through four operating segments namely Heavy Fabrications, Gearing, Industrial Solutions and Corporate.
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.